Application of endometrial stem cells in preparation of drugs for preventing or treating pulmonary fibrosis

A technology of endometrial stem cells and pulmonary fibrosis, applied in the field of biomedicine, can solve the problems of high cost, lack of donated organ resources, no reports, etc., and achieve the effect of improving the phenomenon of pulmonary fibrosis

Pending Publication Date: 2018-12-11
SOUTHERN MEDICAL UNIVERSITY +1
View PDF3 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, drug treatment has relatively large side effects; while lung transplantation is currently the most effective method for the treatment of pulmonary fibrosis, its application is limited due to the lack of donated organ resources, rejection, infection, complications and high cost.
[0005] Recen

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of endometrial stem cells in preparation of drugs for preventing or treating pulmonary fibrosis
  • Application of endometrial stem cells in preparation of drugs for preventing or treating pulmonary fibrosis
  • Application of endometrial stem cells in preparation of drugs for preventing or treating pulmonary fibrosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0031] This embodiment provides a pharmaceutical composition for preventing or treating pulmonary fibrosis. The pharmaceutical composition includes primary cultured endometrial stem cells and sodium chloride aqueous solution. The density of endometrial stem cells in the pharmaceutical composition is 1.0× 10 5 Individual / mL; the mass volume ratio of sodium chloride in the sodium chloride aqueous solution is 0.9%.

[0032] The present embodiment also provides the preparation method of described pharmaceutical composition, it comprises the following steps:

[0033] S1) Sodium chloride is added into water to dissolve and sterilized to obtain an aqueous sodium chloride solution;

[0034] S2) Under sterile conditions, inoculate endometrial stem cells (EMSC) on a 10cm cell culture dish, and place the culture dish at 37°C, CO 2 Culture in a cell incubator with a concentration of 5%; when the density of endometrial stem cells reaches 80% to 100% (preferably 90% to 95%), digest with t...

Embodiment 2

[0037] This embodiment provides a pharmaceutical composition for preventing or treating pulmonary fibrosis. The pharmaceutical composition includes primary cultured endometrial stem cells and sodium chloride aqueous solution. The density of endometrial stem cells in the pharmaceutical composition is 1.0× 10 6 Individual / mL; the mass volume ratio of sodium chloride in the sodium chloride aqueous solution is 0.9%.

[0038] The present embodiment also provides the preparation method of described pharmaceutical composition, it comprises the following steps:

[0039] S1) Sodium chloride is added into water to dissolve and sterilized to obtain an aqueous sodium chloride solution;

[0040] S2) Under sterile conditions, inoculate endometrial stem cells (EMSC) on a 10cm cell culture dish, and place the culture dish at 37°C, CO 2 Culture in a cell incubator with a concentration of 5%; when the density of endometrial stem cells reaches 80% to 100% (preferably 90% to 95%), digest with t...

Embodiment 3

[0043] This embodiment provides a pharmaceutical composition for preventing or treating pulmonary fibrosis. The pharmaceutical composition includes primary cultured endometrial stem cells and sodium chloride aqueous solution. The density of endometrial stem cells in the pharmaceutical composition is 5.0× 10 6 Individual / mL; the mass volume ratio of sodium chloride in the sodium chloride aqueous solution is 0.9%.

[0044] The present embodiment also provides the preparation method of described pharmaceutical composition, it comprises the following steps:

[0045] S1) Sodium chloride is added into water to dissolve and sterilized to obtain an aqueous sodium chloride solution;

[0046] S2) Under sterile conditions, inoculate endometrial stem cells (EMSC) on a 10cm cell culture dish, and place the culture dish at 37°C, CO 2 Culture in a cell incubator with a concentration of 5%; when the density of endometrial stem cells reaches 80% to 100% (preferably 90% to 95%), digest with t...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Thicknessaaaaaaaaaa
Login to view more

Abstract

The invention discloses application of endometrial stem cells in preparation of drugs for preventing or treating pulmonary fibrosis, and belongs to the technical field of biological medicine. The medicine provided by the invention comprises endometrial stem cells, and the solvent of the medicine is an aqueous solution of sodium chloride. The medicine provided by the invention can significantly improve pulmonary fibrosis, regulate the expression levels of alpha-SMA, collagen and IL-6 in lung tissue down, regulate the expression level of IL-10 in lung tissue up, and also regulate the expressionlevel of TNF-alpha in spleen tissue down.

Description

technical field [0001] The invention belongs to the technical field of biomedicine, and particularly relates to the application of endometrial stem cells in the preparation of drugs for preventing or treating pulmonary fibrosis. Background technique [0002] Pulmonary fibrosis is a serious disease characterized by permanent damage to the lungs and accompanied by high mortality, usually due to severe external trauma, autoimmune reactions or adverse drug side effects and other factors that cause permanent damage to the lungs . Studies have shown that the process of pulmonary fibrosis can be roughly divided into the following three stages: the first stage, the lungs are injured or other harmful stimuli, and the extracellular matrix (ECM) of fibroblasts activates the cells; the second stage, the activated ECM Change the structure and phenotype of cells, produce a large amount of ECM, activate the intracellular mitogen-activated protein kinase and nuclear transcription factor pa...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K35/48A61P11/00
CPCA61P11/00A61K35/48
Inventor 徐洋
Owner SOUTHERN MEDICAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap